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S U M M A R Y
B A C K G R O U N D : Persistent respiratory symptoms and
lung function deficits are common after patients with
TB. We aimed to define the burden of post-TB lung
disease (PTLD) and assess associations between symp-
toms and impairment in two high TB incidence
communities.
M E T H O D S : This was a cross-sectional survey of adults
in Cape Town, South Africa who completed TB
treatment 1–5 years previously. Questionnaires, spirom-
etry and 6-minute walking distance (6MWD) were used
to assess relationships between outcome measures and
associated factors.
R E S U LT S : Of the 145 participants recruited (mean age:
42 years, range: 18–75; 55 [38%] women), 55 (38%)
had airflow obstruction and 84 (58%) had low forced
vital capacity (FVC); the mean 6MWD was 463 m
(range: 240–723). Respiratory symptoms were common:
chronic cough (n¼27, 19%), wheeze (n¼61, 42%) and
dyspnoea (modified MRC dyspnoea score 3 or 4: n¼36,
25%). There was poor correlation between FVC or
obstruction and 6MWD. Only low body mass index
showed consistent association with outcomes on multi-
variable analyses. Only 19 (13%) participants had a
diagnosis of respiratory disease, and 16 (11%) currently
received inhalers.
C O N C L U S I O N : There was substantial burden of symp-
toms and physiological impairment in this ‘‘cured’’
population, but poor correlation between objective
outcome measures, highlighting deficits in our under-
standing of PTLD.
K E Y W O R D S : post-TB; spirometry; restriction; physi-
ology; obstruction
TB is one of the most common respiratory infections,
and South Africa has one of the highest TB incidence
rates in the world—around 615 per 100,000 popu-
lation.1,2 There is a growing understanding that the
effects of TB do not end with the completion of anti-
TB chemotherapy.3,4 Residual, post-TB lung disease
(PTLD) includes fibrosis, lung volume loss, cavita-
tion, pleural disease, gas trapping and bronchiectasis,
and can manifest with varying severity.5 In the multi-
national burden of obstructive lung disease study,
people who completed TB treatment had a two-fold
higher risk of developing both obstructive and
restrictive lung disease compared to the general
population.6
There is currently little evidence about how PTLD
phenotypes progress or relate to symptoms. A
prospective study of 405 patients in Malawi found
44% with bronchiectasis and 9% with one destroyed
lobe on high-resolution computed tomography scan-
ning.7 After 1 year, almost a third reported residual
respiratory symptoms, one in five had a decline in
forced expiratory volume in 1 sec (FEV1) of100 ml,
and 16% reported at least one respiratory exacerba-
tion. In a cross-sectional study in suburban Cape
Town, South Africa, approximately half of partici-
pants who had completed TB treatment in the
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previous 5 years reported ongoing respiratory symp-
toms.8
Better understanding of the interplay between
symptoms, physiology and physical performance is
needed, as well as predictive models of who may
develop symptoms or require treatment for those at
highest risk of PTLD. This is most relevant in low-
resource, high-burden settings such as sub-Saharan
Africa, where healthcare resources and diagnostics
are limited.
In the present study, we evaluated the burden of
symptoms, spirometric and physiological impairment
in a community-based population who had success-
fully completed TB treatment, and investigated the
relationship between symptoms and lung function.
METHODS
Setting, participants and sampling
We conducted a cross-sectional study of adults who
had successfully completed TB treatment more than 1
year but less than 5 years prior to study enrolment.
Potential participants who had completed an episode
of TB treatment between 2013 and 2017 were
identified through the Ikhwezi and Ravensmead
Clinic registers in suburban Cape Town, as described
elsewhere,8 and invited to participate. We used
electronic TB registers from both primary healthcare
facilities to obtain a random sample of individuals
who were recorded for treatment during this time
frame, and with a documented standard treatment
outcome of either ‘‘cure’’ or ‘‘treatment completed’’.
Study recruitment and follow-up occurred between
October and December 2018 (Ikhwezi) and March
and November 2019 (Ravensmead). Individuals were
contacted during study visits at the home address
recorded in the treatment register. Individuals were
eligible for this study if they were at least 18 years old,
had at least one episode of treated TB (as per list), and
provided informed written consent. Exclusion criteria
were pregnancy, currently receiving TB treatment,
contra-indications to performing spirometry and
acute illness (likely to introduce measurement error).
Outcomes
Primary outcome was the prevalence of symptoms,
physiological impairment and spirometric abnormal-
ities. Secondary outcomes included correlation be-
tween the primary outcomes and a model for
spirometric and 6-min walking distance (6MWD)
results.
Data collection
Participants completed the IMPALA (International
Multidisciplinary Programme to Address Lung
Health and TB in Africa) symptoms, smoking,
environmental exposures, life exposures, previous
episodes of TB and nutrition questionnaires.9 Data
were collected electronically using KoBo Toolbox
(Harvard Humanitarian Initiative, Cambridge, MA,
USA).10 Breathlessness was rated using the modified
Medical Research Council (mMRC) scale.11 Demo-
graphic data were captured and managed using
REDCap (Vanderbilt University, Nashville, TN,
USA) electronic data capture tools hosted at Stellen-
bosch University, Tygerberg, South Africa.12 Spirom-
etry and the 6-min walking test were conducted at the
study locations. Spirometry was performed before
and after inhaled salbutamol 400 mcg via a metered-
dose inhaler using EasyOnew (ndd Medical Tech-
nologies, Zurich, Switzerland) device according to
the American Thoracic Society/European Respira-
tory Society guidelines. Post-bronchodilator spirom-
etry data are presented here.Normal spirometric
ranges were defined by GLI (Global Lung Function
Initiative) 2012, and abnormal results were defined
those less than the lower limit of normal (LLN) (Z-
score ,–1.64).13
Statistical methods
Data were presented as means, standard deviations,
medians, ranges or percentages based on the type and
distribution of data. Pearson’s and Spearman’s
correlation were used for the correlation analysis.
Student’s t-test, analysis of variance (ANOVA), v2
and Kruskal-Wallis tests were used for univariable
analysis. Linear or logistic regression analysis was
used for the multivariable analysis. Outcome vari-
ables were forced vital capacity (FVC) % predicted,
6-min walking distance (6MWD) and forced expira-
tory volume in 1 s (FEV1)/FVC , LLN. Variables
were included in the model based on exposures of
interest and possible confounders. Variables were
retained to create the smallest Akaike Information
Criterion (AIC) in the final backwards multivariable
regression analysis. Significance was defined as P ,
0.05, 95% confidence intervals (CIs) have been
provided where appropriate. Data were analysed
using R (R Computing, Vienna, Austria).14
Ethical considerations
Ethical approval was obtained from Stellenbosch
University, Tygerberg, South Africa; (N18/05/056)
and the Liverpool School of Tropical Medicine,
Liverpool, UK (18-050). Permission to conduct the
study was obtained from the Western Cape Depart-
ment of Health, Cape Town, South Africa; all
participants provided written informed consent prior
to participating in the study.
RESULTS
Descriptive data
A total of 432 participants from the registers were
contacted, 39 had died (9.0%) and 277 were invited
to take part (Figure 1). We recruited 145 study
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participants (Figure 1), of which 55 (38%) were
women. The mean age was 42 years (range 18–75,
Table 1). Over half of the participants left school at or
before age 15 (66%). Of the 145 participants, 24
were living with HIV, 26 had hypertension and 19
diabetes; 19 had a respiratory disease diagnosis and
16 were prescribed inhalers. Cough, phlegm produc-
tion, and wheeze were present in respectively 19%,
17% and 42% of participants; 55 (38%) had been
treated more than once for TB, with a range of up to 6
times. Most participants reported having their first
episode of TB as adults. Seven (5%) did not complete
treatment on at least one occasion and 10 (7%) had
been treated for multi- or extensively drug-resistant
TB (MDR- and XDR-TB) at least once (Figure 1).
There was a high prevalence but low intensity of
smoking: 100 (69%) reported current or previous
smoking, but participants only accumulated a median
of 6.7 pack-years; 51 (35%) participants reported
smoking substances other than cigarettes, the most
common being cannabis and waterpipe.
About one third lived close to roads (n¼46, 32%),
and walking was the main mode of travel for 55
(38%). Prolonged exposure to dusts, gases and fumes
was reported by 90 participants (62%); 82 (59%)
reported having experienced lack of food and 71
(49%) consumed alcohol (median: 21 units/week,
interquartile range [IQR] 7.5–38). The median body
mass index (BMI) was 20.7 kg/m2 (IQR 18.5–25.6).
Outcome data
Of the 145 participants, 82 (57%) reported minimal
dyspnoea (mMRC 0), but 25% described significant
breathlessness symptoms (mMRC 3 or 4, see Supple-
mentary Table S1). The mean FEV1 was 2.24 L
(range: 0.40–4.67), and a mean of 68% predicted
FEV1. The mean FVC was 3.03 L, a mean of 75%
predicted. The median FEV1/FVC ratio was 0.75, and
55 (38%) of participants had obstruction defined by
the LLN. The mean 6MWD was 463 m (range: 240–
723); 31 participants did not complete a 6-minute
walk test (Table 1).
Uni- and multivariable analysis
The main outcome variables were FVC (% predicted)
to measure restriction, FEV1/FVC ratio as per the
LLN (to measure obstruction) and 6MWD (as a
physiological measure). For the univariable analysis,
all participants with data for that variable were
included. All those with fully completed data sets
across all variables (n ¼ 107) were included in the
multivariable analysis.
There was no evidence of correlation between the
three outcome variables: FVC vs. obstruction (point-
biserial correlation coefficient –0.11, 95% CI –0.30
Figure 1 Flowchart of participant eligibility and inclusion into the study. *Participants did not
have 6MWD due to delayed start of staff (n¼8), low resting peripheral saturations (,94%, n¼3),
injury (n¼ 1), patient preference (n¼ 1), unknown (n¼ 18). 6MWD¼ 6-min walking distance.
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to 0.08), FVC vs. 6MWD (Pearson coefficient 0.07,
95% CI –0.11 to 0.25) and obstruction vs. 6MWD
(point-biserial correlation coefficient –0.07, 95% CI
–0.24 to 0.12), nor between FEV1 in participants with
obstruction and 6MWD (see Supplementary Figures).
mMRC scores were not related to shorter 6MWD
(one-way ANOVA P ¼ 0.13; F(4,19) ¼ 1.82). Those
with mMRC scores of 2 or 3 appeared to have a
reduced 6MWD, but this was not maintained for
those with an mMRC score of 4 (Figure 2).
For the 84 participants with low FVC (Z-score
,1.64 of normal), the mean 6MWD was 465 m
compared to 458 m of patients with normal FVC (P¼
0.69, 95% CI for difference of the mean: –43 to 28).12
The mean 6MWD in patients with airflow obstruc-
tion was 450 m, compared to 469 m in patients
without airflow obstruction (P ¼ 0.31, 95% CI for
difference of mean –19 to 56).
FVC (% predicted), BMI, alcohol consumption and
chronic bronchitis symptoms were statistically signif-
icantly associated in univariable analysis (Table 2).
BMI, alcohol consumption and symptoms of chronic
bronchitis were present in the final multivariable,
adjusted regression model (R2 0.14; AIC 594).
6MWD, age, BMI, highest level of education, HIV
Table 1 Baseline participant characteristics




Age, years, mean (range) 42 (18–75)
Highest level of education
,Grade 10 73 (50)
Grade 10 23 (16)
Grade 10–12 33 (29)









Cardiac disease 4 (3)
Respiratory disease diagnosis 19 (13)
Asthma 14
Post-TB bronchiectasis and COPD 1
Other 4
Inhalers received 16 (11)
Asthavent (short-acting beta-agonist) 5




mMRC 0 82 (57)
mMRC 1 20 (14)
mMRC 2 7 (5)
mMRC 3 17 (12)
mMRC 4 19 (13)
Chronic cough for at least 3 months/
year 27 (19)
Chronic phlegm for at least 3 months/
year 24 (17)
Presence of wheezing attacks in the last
12 months 61 (42)
Number of wheezing attacks in the last
12 months, median (range) [IQR] 2 (1–12) [1–4]
Previous TB







Age at first TB, years, median (range)
[IQR] 32 (8–70) [23–42]
Number of those ever having had less
than 6 months of treatment 7 (5)
Drug susceptibility of previous TB episodes
MDR/XDR-TB 10 (7)
Drug-susceptible TB 135 (93)
6MWT
6MWT performed 114 (79)
6MWT distance, m, mean (range) 463 (240–723)
Spirometry
FEV1, L, mean (range) 2.24 (0.40–4.67)
FEV1, % predicted, mean (range) 68 (20–117)
FVC, L, mean (range) 3.03 (0.65–5.50)
FVC, % predicted, mean (range) 75 (22–125)
Low FVC by LLN 84 (58)
FEV1/FVC ratio, median (range) 0.75 (0.30–1.00)





Patient characteristic n (%)*
Ex 15 (10)
Never 45 (31)
Smoking duration, years, mean (range) 23 (1–55)
Smoking, pack years, median (range)
[IQR] 6.7 (0.1–43) [3.5–13.3]
Smoked substances other than
cigarettes 51 (35)




Tik (crystal methamphetamine) 5
Mandrax (methaqualone) 8
Other 4
Exposure to air pollution
Residing beside a major road 46 (32)
Prolonged (.15 h) exposure to vapours,
dusts, gases or fumes at home or in
workplace 90 (62)




Not specified 43 (29)
Nutrition
Ever experienced lack of food 82 (57)
Alcohol use 71 (49)
Units of alcohol consumed/week,
median [IQR] 21 [7.5–38]
BMI, kg/m2, median [IQR] 20.7 [18.5–25.6]
* Missing percentages due to rounding.
† Participants can have multiple comorbidities.
ART ¼ antiretroviral treatment; COPD ¼ chronic obstructive pulmonary
disease; mMRC ¼ modified Medical Research Council; IQR ¼ interquartile
range; MDR-TB¼multidrug-resistant TB; XDR-TB¼ extensively drug-resistant
TB; 6MWT¼6-min walking test; FEV1¼forced expiratory volume in 1 sec; FVC
¼ forced vital capacity; LLN¼ lower limit of normal; BMI¼ body mass index.
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status, age at first TB, FEV1 (in L) and FVC (in L)
were statistically significant in the univariable
analysis (Table 3). The multivariable linear regres-
sion model included age, BMI, alcohol consumption,
highest level of education, HIV status, chronic
cough, chronic bronchitis, smoking status and
smoking substances other than cigarettes (R2 0.37;
AIC 920).
Spirometric obstruction was statistically signifi-
cantly influenced only by BMI in the uni- and multi-
variable logistic regression analysis (Table 4). The
final multivariable logistic regression model included
BMI, chronic cough, chronic bronchitis, alcohol
consumption and 6MWD. This model accounted
for 70% of the variation in the data (AIC 128.3; Cox-
Snell R2 0.18; Nagelkerke R 0.25).
DISCUSSION
This cohort of 145 participants who had successfully
completed TB treatment between 1 and 5 years
previously had high burden of symptoms, short
6MWD and spirometric obstruction. We were unable
to find strong associations between risk factors and
symptoms, spirometric or physiological impairment,
and there was poor correlation between outcome
measures themselves (spirometric and functional).
Despite the high burden of respiratory abnormal-
ities, only 19 participants had a formal diagnosis of
respiratory disease and only 16 received inhalers at
enrolment. Almost a third reported significant
breathlessness (mMRC 2), more than 40% attacks
of wheezing, and about 1 in 5 chronic cough and
phlegm. It is surprising to note that 38% had chronic
airflow obstruction and the mean 6MWD was 463 m,
as this was a young community population. A
hundred participants were current or ex-smokers;
however, smoking intensity was low (median con-
sumption: 6.7 pack years), implying cigarette smoke a
less likely cause for symptoms. Smoking other
substances and exposures to potentially damaging
inhalants were common; however, neither these, nor
cigarette smoking were associated with objective
outcome measures. Seventeen participants reported
at least three previous episodes of TB and most first
contracted TB as middle-aged adults, but the number
of TB episodes, drug resistance and age of first
episode were not associated with outcomes, as has
been suggested elsewhere.15
A very high prevalence of spirometric obstruction
has been described in previous multi-centre, multi-
national studies.16 A similar study in rural South
Africa found comparatively more preserved lung
function and fewer symptoms but much reduced
6MWD (mean: 294 m) compared to our popula-
tion.17 A Malawian cohort demonstrated lower
symptom burden than our population, with 12%
having symptom-related impairment in their ability
Figure 2 Boxplot of mMRC score vs. 6MWD (m). Boxplots show median, upper and lower
quartiles, with total range and individual data points. 6MWD¼ 6-min walking distance; mMRC¼
modified Medical Research Council.
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to work 1 year after treatment completion, with a
mean 6MWD of 611 m.7 Whether there is an effect of
urbanisation on PTLD needs to be established.
The associations between various commonly re-
ported objective measures of respiratory function
were poor. This adds complexity to the syndrome of
PTLD, which is known for its heterogeneity, and
amplifies the difficulty in the epidemiological mea-
surement and modelling of disability in PTLD. The
persistent symptomatology observed and the well-
described excess mortality (9% of our sample
population had died) cannot be ignored;18,19 howev-
er, our knowledge of the interplay between spirom-
etry, symptoms and physiology in PTLD is
incomplete. Studies of PTLD in Mexico and the
United States described a negative correlation be-
tween spirometry abnormalities and symptoms.20,21
These correlations have also been investigated in
other respiratory conditions, such as asthma, with
inconsistent results.22–27 In chronic obstructive pul-
monary disease (COPD), dyspnoea has been estab-
lished as a marker for mortality, with mMRC scores
of 3 or 4 associated with a relative risk of death of 8.3
and 61 respectively.28 These conflicting data indicate
that for now we should continue investigating PTLD
patients multi-dimensionally until better outcome
data are available.
The models derived suggest some factors may be
associated with the spirometry, physiological and
symptomatic impairments described. Chronic cough
or chronic bronchitis symptoms appeared in final
models for 6MWD and FVC but not spirometric
obstruction, and could be explored as one potential
screening tool for impairment. Low BMI and alcohol
use were frequently associated, but the reason for the
association is unclear. Both could be confounders,
associated with a common unknown independent
variable, for example, poor nutrition or poor social
circumstances, or both could be effect modifiers in
the pathway to PTLD, or potentially even a
Table 2 Results of univariable and multivariable linear regression analysis for FVC (% predicted)*
Variable
Univariable analysis Multivariable analysis
Unadjusted coefficient
estimate (95% CI) P value
Adjusted coefficient
estimate (95% CI) P value
Male sex –4.80 (–11.52 to 1.92) 0.16
Age, years –0.05 (–0.29 to 0.19) 0.70
BMI 0.49 (0.00 to 1.00) 0.05 0.61 (0.13 to 1.10) 0.01†
Alcohol consumption 6.89 (0.53 to 13.25) 0.03† 9.22 (3.06 to 15.38) ,0.01†
Highest level of
education‡
Linear coefficient: –2.29 (–8.81 to 4.24) 0.49
Quadratic coefficient: –3.57 (–10.69 to 3.56) 0.32
Cubic coefficient: –4.43 (–12.11 to 3.25) 0.26
HIV status Positive: 7.33 (–1.75 to 16.42) 0.11
Unknown: –2.26 (–15.36 to 10.84) 0.73
Respiratory disease
diagnosis
Yes: –9.61 (–21.86 to 2.64) 0.12
Unknown: 5.96 (–13.56 to 25.48) 0.55
mMRC Score‡ Linear: –2.87 (–10.98 to 5.24) 0.48
Quadratic: 11.15 (–0.03 to 22.34) 0.05
Cubic: 1.57 (–8.55 to 11.69) 0.76
6MWD, m 0.00 (–0.02 to 0.05) 0.62
Chronic cough for at
least 3 months per
year
–8.88 (–17.82 to 0.06) 0.05
Chronic bronchitis
symptoms§
Present: –8.16 (–16.35 to 0.04) 0.05 –10.35 (–18.28 to –2.41) 0.01†
Unknown: –12.37 (–29.20 to 4.46) 0.15 Unknown: –14.68 (–30.69 to 1.32) 0.07
Number of times treated
for TB (1, 2, 3)
Linear coefficient: –1.50 (–9.55 to 6.55) 0.71
Quadratic coefficient: –2.67 (–9.64 to 4.30) 0.45
Age at first TB, years –0.02 (–0.27 to 0.22) 0.84
Ever not completed
treatment
–1.75 (–14.87 to 11.38) 0.79
Ever had MDR/XDR-TB –10.99 (–30.54 to 8.56) 0.27
Smoking status Ex: 3.03 (–10.31 to 16.37) 0.65
Never: 2.87 (–4.40 to 10.14) 0.44
Ever smoked substance
other than cigarettes
3.56 (–3.15 to 10.27) 0.30 5.06 (–1.33 to 11.44) 0.12
Any prolonged (.15 h)
exposure to vapours,
dusts, gases or fumes
at home or in job
–0.78 (–7.61 to 6.04) 0.82
Final model fit Adjusted R2: 0.14 AIC: 594
* Variables were included based on exposures of interest and possible confounders. Statistically significant variables as per final backwards multivariable regression
analysis. For binary variables, the other group is the comparator.
† P , 0.05.
‡ mMRC and education level treated as ordinal categorical values.
§ Defined as productive cough for at least 3 months in the previous 2 years.
FVC¼ forced vital capacity; CI¼ confidence interval; BMI¼ body mass index; mMRC¼modified medical research council; 6MWD¼ 6-minute walking distance;
MDR-TB¼multidrug- resistant; XDR-TB¼ extensively drug-resistant TB; AIC¼Akaike Information Criterion.
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consequence (rather than a cause) of chronic lung
impairment. The usual cautions need to be employed
when interpreting cross-sectional associations and
attributing either effect modification or prediction
to the outcome.
Although participants were assessed in detail
regarding their symptoms, spirometry and functional
capacity, we did not consider their radiological
findings. Chest X-ray is likely to be a less sensitive
measure of post-TB impairment than spirometry, as it
cannot identifypredominantly small-airway PTLD.29
The baseline data reflect the population sampled—
limited education, almost 20% HIV prevalence, with
an experience of food shortages and a low–normal
BMI, so the high burden of observed PTLD could
have particularly significant economic, morbidity and
mortality implications in this vulnerable population.
Clearly there is a need for a better understanding
of the pathophysiology of PTLD and the relation-
ship between objective physiological measures,
symptoms and meaningful outcomes such as mor-
tality, exacerbations and morbidity (including psy-
chosocial impacts). It is likely that a multimodal
approach will be needed, analogous to that used for
other respiratory diseases, for example, the BODE
(Body-mass index, airflow Obstruction, Dyspnea,
and Exercise) index in COPD.30,31 Developing such
a tool for PTLD would be helpful to risk stratify
patients in limited healthcare settings such as sub-
Saharan Africa. Although self-selection through
participation and the sample size may have impact-
ed our study findings, unlike previous studies of
PTLD, patients were not actively healthcare-seeking
and were selected at random from a TB register
between 1 and 5 years after treatment completion.
These high rates of residual abnormalities after
Table 3 Results of univariable and multivariable linear regression analysis for 6-minute walking distance*
Variable
Univariable analysis Multivariable analysis
Unadjusted coefficient
estimate (95% CI) P value
Adjusted coefficient
estimate (95% CI) P value
Male sex 15.80 (–19.09 to 50.70) 0.37
Age, years –3.22 (–4.30 to –2.16) ,0.01† –2.24 (–3.47 to 1.01) ,0.01†
BMI –4.72 (–7.20 to –2.23) ,0.01† –4.30 (–6.61 to –1.99) ,0.01†
Alcohol consumed –16.84 (–50.25 to 16.56) 0.32 –23.30 (–51.05 to 4.45) 0.10
Highest level of
education‡
Linear coefficient: 24.70 (–7.58 to 56.99) 0.13 Linear coefficient: –0.61 (–29.99 to 28.77) 0.97
Quadratic coefficient: –29.01 (–64.27 to 6.25) 0.11 Quadratic coefficient: –2.41 (–36.16 to 31.34) 0.89
Cubic coefficient: –48.18 (–86.19 to –10.18) 0.01† Cubic coefficient: –52.95 (–86.33 to –19.57) ,0.01†
HIV status Positive: 49.29 (2.73 to 95.85) 0.04† Positive: 49.55 (9.31 to 89.79) 0.02†
Unknown: 8.76 (–58.39 to 75.90) 0.80 Unknown: 13.16 (–42.76 to 69.08) 0.65
Respiratory disease
diagnosis
Yes: –26.76 (–90.64 to 37.13) 0.41
Unknown 14.16 (–87.62 to 115.94) 0.78
mMRC Score‡ Linear: –37.92 (–80.13 to 4.28) 0.08
Quadratic: 9.87 (–48.34 to 68.09) 0.74
Cubic: 19.16 (–33.51 to 71.83) 0.47
Chronic cough for at
least 3 months per
year
–18.92 (–65.78 to 27.95) 0.43 78.01 (–4.72 to 160.74) 0.07
Chronic bronchitis
symptoms§
Yes: –31.92 (–74.85 to 11.02) 0.14 Yes: –79.01 (–156.59 to –1.43) 0.05†
Unknown: 8.06 (–80.18 to 96.30) 0.86 Unknown: 21.07 (–50.71 to 92.85) 0.57
Number of times treated
for TB (1, 2, 3)
Linear coefficient: –5.72 (–47.38 to 35.94) 0.79
Quadratic coefficient: –6.94 (–43.00 to 29.12) 0.70
Age at first TB, years –2.89 (–4.01 to –1.77) ,0.01†
Ever not completed
treatment
–4.18 (–71.97 to 63.61) 0.90
Ever had MDR/XDR-TB 47.09 (–54.05 to 148.22) 0.36
Smoking status Ex: 19.21 (–49.67 to 88.08) 0.58 Ex: 58.41 (1.16 to 115.66) 0.05
Never: 14.28 (–23.26 to 51.28) 0.45 Never: 13.72 (–23.64 to 51.08) 0.47
Ever smoked substance
other than cigarettes
25.75 (–8.72 to 60.23) 0.14 23.91 (–7.41 to 55.23) 0.14
Any prolonged (.15 h)
exposure to vapours,
dusts, gases or fumes
at home or in job
–7.59 (–42.80 to 27.63) 0.67
FEV1, L 35.00 (13.91 to 56.09) ,0.01
†
FVC, % predicted 0.25 (–0.75 to 1.24) 0.62
Obstruction by LLN –19.13 (–54.67 to 16.41) 0.29
Final model fit Adjusted R2: 0.37 AIC: 920
* Variables were included based on exposures of interest and possible confounders. Statistically significant variables as per final backwards multivariable regression
analysis. For binary variables, the other group is the comparator.
† P , 0.05.
‡ mMRC and education level treated as ordinal categorical values.
§ Defined as productive cough for at least 3 months in the previous 2 years.
CI ¼ confidence interval; BMI ¼ body mass index; mMRC ¼ modified medical research council; MDR-TB ¼ multidrug-resistant TB; XDR-TB ¼ extensively drug-
resistant TB; FEV1¼ forced expiratory volume in 1 sec; FVC¼ forced vital capacity; LLN¼ lower limit of normal; AIC¼Akaike Information Criterion.
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successful treatment, combined with low rates of
chronic respiratory diagnosis or treatment, again
highlights the need to look beyond usual outcome
measures in TB trials and control programmes. Given
the significant symptoms and functional impairment in
this young population, urgent prognostic assessments
for PTLD are needed, and pulmonary rehabilitation
programmes may play a significant role in its
treatment.32–35 More work is required on the long-
term evolution of PTLD to identify individuals at risk
of chronic PTLD and to investigate effective preven-
tion and treatment strategies.
CONCLUSION
This population exhibited a high burden of self-
reported symptoms, airflow obstruction and func-
tional impairment 1–5 years after TB treatment
completion, yet only a minority had received a
diagnosis of chronic disease or were receiving
treatment. There was poor correlation between
physiology, functional capacity and symptoms, with
only low BMI most consistently associated with
outcomes. This highlights the need for a better
understanding of disease pathophysiology and mul-
timodal assessments to determine meaningful objec-
tive measurements in PTLD. More work is needed on
the prognosis of and interventions for PTLD,
considering that more than 58 million people have
survived TB in the last two decades alone.
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Table 4 Results of univariable and multivariable logistic regression analysis for spirometric obstruction (FEV1/FVC less than lower
limit of normal)*
Variable
Univariable analysis Multivariable analysis
OR (95% CI) P value aOR (95% CI) P value
Male sex 1.31 (0.56–3.17) 0.54
Age, years 1.02 (0.99–1.05 0.31
BMI 0.91 (0.83–0.99) 0.04† 0.88 (0.79–0.96) 0.01†
Alcohol consumed 0.67 (0.30–1.51) 0.34 0.85 (0.17–4.25) 0.07
Highest level of education‡ Linear: 0.53 (0.22–0.64) 0.14
Quadratic: 1.96 (0.72–6.13) 0.21
Cubic: 3.19 (1.04–12.71) 0.06
HIV status Positive: 1.34 (0.42–4.01) 0.61
Unknown: 1.67 (0.31–8.12) 0.52
mMRC Score‡ Linear: 1.98 (0.68–5.63) 0.20
Quadratic: 0.39 (0.09–1.57) 0.17
Cubic: 0.39 (0.09–1.37) 0.16
6MWD, m 1.00 (0.18–15.30) 0.29 0.99 (0.98–1.01) 0.91
Chronic cough for at least 3 months
per year
0.92 (0.27–2.79) 0.89 0.00 (0–‘) 0.99
Chronic bronchitis symptoms§ Yes: 2.01 (0.73–5.49) 0.17 OR (yes): 0.00 (0.00–‘) 0.99
Unknown: 2.46 (0.28–21.46) 0.38 OR (unknown): 3.76 (0.34–44.05) 0.26
Number of times treated for TB (1, 2,
3)
Linear: 1.98 (0.75–5.27) 0.16
Quadratic: 0.96 (0.42–2.24) 0.93
Age at first TB, years 1.00 (0.97–1.03) 0.87
Ever not completed treatment 1.59 (0.30–7.64) 0.56
Ever had MDR/XDR-TB 4.30 (0.40–94.54) 0.24
Smoking status Ex: 0.75 (0.10–3.77) 0.74
Never: 0.77 (0.30–1.89) 0.57
Ever smoked substance other than
cigarettes
1.79 (0.78–4.13) 0.17
Any prolonged (.15 h) exposure to
vapours, dusts, gases or fumes at
home or in job
0.59 (0.25–1.36) 0.21
Final model AIC: 128.3
Cox–Snell R2: 0.18
Nagelkerke: 0.25
* Variables were included based on exposures of interest and possible confounders. Statistically significant variables as per final backwards multivariable regression
analysis. For binary variables, the other group is the comparator. No obstruction is comparator group for all ORs.
† P , 0.05.
‡ mMRC and education level treated as ordinal categorical values.
§ Defined as productive cough for at least 3 months in the previous 2 years.
FEV1¼ forced expiratory volume in 1 sec; FVC¼ forced vital capacity; OR¼odds ratio; CI¼confidence interval; aOR¼adjusted OR; BMI¼body mass index; mMRC
¼modified medical research council; 6MWD¼ 6-min walking distance; MDR-TB¼multidrug-resistant TB; XDR-TB¼ extensively drug-resistant TB; AIC¼Akaike
Information Criterion.
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R É S U M É
C O N T E X T E : Des symptômes respiratoires persistants
et des déficits de la fonction pulmonaire sont fréquents
après une TB. Nous avons tenté de définir le poids de la
maladie pulmonaire post-TB (PTLD) et d’évaluer les
associations entre symptômes et troubles respiratoires,
dans deux communautés à incidence élevée.
M É T H O D E S : Enquête transversale auprès d’adultes au
Cap, Afrique du Sud. Ceux-ci ont rempli questionnaire
relatif au traitement de la TB dans les 1–5 années
précédentes. Les questionnaires, une spirométrie et un
test de marche de 6 minutes (6MWD) ont été utilisés
pour évaluer les relations entre mesures de résultats et
facteurs associés.
R É S U LTAT S : Nous avons recruté 145 participants
d’âge moyen 42 ans (fourchette 18–75) dont 55
femmes (38%) ; 55 (38%) avaient une obstruction des
voies aériennes, 84 (58%) une diminution de la FVC
(capacité vitale forcée) et le 6MWD moyen était de 463
m (fourchette 240–723). Les symptômes respiratoires
ont été fréquents : toux chronique (n ¼ 27, 19%),
sifflement (n ¼ 61, 42%) et dyspnée (score modifié de
Medical Research Council de dyspnée 3 ou 4 (n ¼ 36,
25%). Il y a eu une corrélation médiocre entre FVC ou
obstruction et 6MWD. Seuls les patients ayant un indice
de masse corporelle faible ont mis en évidence une
association cohérente avec les résultats d’analyse
multivariable. Seulement 19 (13%) participants ont eu
un diagnostic de maladie respiratoire et 16 (11%) ont
reçu des inhalateurs.
C O N C L U S I O N : Il y a un poids substantiel de
symptômes et de handicap physiologique dans cette
population « guérie », mais une corrélation médiocre
entre les mesures de résultats objectives, ce qui met en
lumière le déficit de notre compréhension de la PTLD.
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